Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
Status:
Completed
Trial end date:
2021-08-11
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, 96-week open-label study of the safety and virologic
efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC)
initiated during acute HIV infection (AHI).
Phase:
N/A
Details
Lead Sponsor:
Cynthia L Gay, MD University of North Carolina, Chapel Hill